Literature DB >> 22429089

Angiotensin II and oxidative stress in the failing heart.

Daniela Zablocki1, Junichi Sadoshima.   

Abstract

SIGNIFICANCE: Despite recent medical advances, cardiovascular disease and heart failure (HF) continue to be major health concerns, and related mortality remains high. As a result, investigation of the mechanisms involved in the development of HF continues to be an active field of study. RECENT ADVANCES: The renin-angiotensin system (RAS) and its effector molecule, angiotensin (Ang) II, affect cardiac function through both systemic and local actions, and have been shown to play a major role in cardiac remodeling and dysfunction in the failing heart. Many of the downstream effects of AngII signaling are mediated by elevated levels of reactive oxygen species (ROS) and oxidative stress, which have also been implicated in the pathology of HF. CRITICAL ISSUES: Inhibitors of the RAS have proven beneficial in the treatment of patients at risk for and suffering from HF, but remain only partially effective. ROS can be generated from several different sources, and the oxidative state is normally tightly regulated in the heart. How AngII increases ROS levels and causes dysregulation of the cardiac oxidative state has been the subject of considerable interest in recent years. FUTURE DIRECTIONS: A better understanding of this process and the mechanisms involved should lead to the development of more effective HF therapies and improved outcomes.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22429089      PMCID: PMC3771547          DOI: 10.1089/ars.2012.4588

Source DB:  PubMed          Journal:  Antioxid Redox Signal        ISSN: 1523-0864            Impact factor:   8.401


  154 in total

1.  2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation.

Authors:  Mariell Jessup; William T Abraham; Donald E Casey; Arthur M Feldman; Gary S Francis; Theodore G Ganiats; Marvin A Konstam; Donna M Mancini; Peter S Rahko; Marc A Silver; Lynne Warner Stevenson; Clyde W Yancy
Journal:  Circulation       Date:  2009-03-26       Impact factor: 29.690

Review 2.  Direct renin inhibitors as antihypertensive agents.

Authors:  Zafar H Israili; Manuel Velasco; Valmore Bermúdez
Journal:  Am J Ther       Date:  2010 May-Jun       Impact factor: 2.688

3.  Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction.

Authors:  JiuChang Zhong; Ratnadeep Basu; Danny Guo; Fung L Chow; Simon Byrns; Manfred Schuster; Hans Loibner; Xiu-hua Wang; Josef M Penninger; Zamaneh Kassiri; Gavin Y Oudit
Journal:  Circulation       Date:  2010-08-02       Impact factor: 29.690

4.  Effects of angiotensin metabolites in the coronary vascular bed of the spontaneously hypertensive rat: loss of angiotensin II type 2 receptor-mediated vasodilation.

Authors:  Els Moltzer; Anna V A Verkuil; Richard van Veghel; A H Jan Danser; Joep H M van Esch
Journal:  Hypertension       Date:  2009-12-21       Impact factor: 10.190

5.  Nox2 NADPH oxidase promotes pathologic cardiac remodeling associated with Doxorubicin chemotherapy.

Authors:  Youyou Zhao; Declan McLaughlin; Emma Robinson; Adam P Harvey; Michelle B Hookham; Ajay M Shah; Barbara J McDermott; David J Grieve
Journal:  Cancer Res       Date:  2010-09-30       Impact factor: 12.701

Review 6.  Autophagy, redox signaling, and ventricular remodeling.

Authors:  Narasimman Gurusamy; Dipak K Das
Journal:  Antioxid Redox Signal       Date:  2009-08       Impact factor: 8.401

7.  Renin-angiotensin inhibition reverses advanced cardiac remodeling in aging spontaneously hypertensive rats.

Authors:  Norihisa Ito; Mitsuru Ohishi; Koichi Yamamoto; Yuji Tatara; Atsushi Shiota; Norihiro Hayashi; Norio Komai; Yoshihiro Yanagitani; Hiromi Rakugi; Toshio Ogihara
Journal:  Am J Hypertens       Date:  2007-07       Impact factor: 2.689

8.  Cardiac overexpression of angiotensin converting enzyme 2 protects the heart from ischemia-induced pathophysiology.

Authors:  Shant Der Sarkissian; Justin L Grobe; Lihui Yuan; Dhruv R Narielwala; Glenn A Walter; Michael J Katovich; Mohan K Raizada
Journal:  Hypertension       Date:  2008-02-04       Impact factor: 10.190

9.  Reactive oxygen species (ROS)-induced ROS release: a new phenomenon accompanying induction of the mitochondrial permeability transition in cardiac myocytes.

Authors:  D B Zorov; C R Filburn; L O Klotz; J L Zweier; S J Sollott
Journal:  J Exp Med       Date:  2000-10-02       Impact factor: 14.307

10.  Involvement of NADPH oxidase in age-associated cardiac remodeling.

Authors:  Mingyi Wang; Jing Zhang; Simon J Walker; Rafal Dworakowski; Edward G Lakatta; Ajay M Shah
Journal:  J Mol Cell Cardiol       Date:  2010-01-15       Impact factor: 5.000

View more
  33 in total

Review 1.  Inflammation in nonischemic heart disease: initiation by cardiomyocyte CaMKII and NLRP3 inflammasome signaling.

Authors:  Takeshi Suetomi; Shigeki Miyamoto; Joan Heller Brown
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-08-23       Impact factor: 4.733

2.  Collagen receptor cross-talk determines α-smooth muscle actin-dependent collagen gene expression in angiotensin II-stimulated cardiac fibroblasts.

Authors:  Harikrishnan V; Allen Sam Titus; Randy T Cowling; Shivakumar Kailasam
Journal:  J Biol Chem       Date:  2019-11-07       Impact factor: 5.157

3.  Angiotensin-(1-7) administration benefits cardiac, renal and progenitor cell function in db/db mice.

Authors:  A M Papinska; N M Mordwinkin; C J Meeks; S S Jadhav; K E Rodgers
Journal:  Br J Pharmacol       Date:  2015-07-30       Impact factor: 8.739

4.  Intracoronary Cytoprotective Gene Therapy: A Study of VEGF-B167 in a Pre-Clinical Animal Model of Dilated Cardiomyopathy.

Authors:  Felix Woitek; Lorena Zentilin; Nicholas E Hoffman; Jeffery C Powers; Isabel Ottiger; Suraj Parikh; Anna M Kulczycki; Marykathryn Hurst; Nadja Ring; Tao Wang; Farah Shaikh; Polina Gross; Harinder Singh; Mikhail A Kolpakov; Axel Linke; Steven R Houser; Victor Rizzo; Abdelkarim Sabri; Muniswamy Madesh; Mauro Giacca; Fabio A Recchia
Journal:  J Am Coll Cardiol       Date:  2015-07-14       Impact factor: 24.094

Review 5.  How cardiomyocytes sense pathophysiological stresses for cardiac remodeling.

Authors:  Zaffar K Haque; Da-Zhi Wang
Journal:  Cell Mol Life Sci       Date:  2016-10-06       Impact factor: 9.261

Review 6.  Antioxidant-based therapies for angiotensin II-associated cardiovascular diseases.

Authors:  Erin G Rosenbaugh; Krupa K Savalia; Devika S Manickam; Matthew C Zimmerman
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-04-03       Impact factor: 3.619

7.  HO-1 induction improves the type-1 cardiorenal syndrome in mice with impaired angiotensin II-induced lymphocyte activation.

Authors:  Sumit R Monu; Paola Pesce; Komal Sodhi; Massimo Boldrin; Nitin Puri; Larisa Fedorova; David Sacerdoti; Stephen J Peterson; Nader G Abraham; Attallah Kappas
Journal:  Hypertension       Date:  2013-06-10       Impact factor: 10.190

Review 8.  Interplay of cardiovascular mediators, oxidative stress and inflammation in liver disease and its complications.

Authors:  Csaba Matyas; György Haskó; Lucas Liaudet; Eszter Trojnar; Pal Pacher
Journal:  Nat Rev Cardiol       Date:  2020-09-30       Impact factor: 32.419

9.  Hemodynamic and transcriptomic studies suggest early left ventricular dysfunction in a preclinical model of severe mitral regurgitation.

Authors:  Daniella Corporan; Daisuke Onohara; Alan Amedi; Maher Saadeh; Robert A Guyton; Sandeep Kumar; Muralidhar Padala
Journal:  J Thorac Cardiovasc Surg       Date:  2020-10-08       Impact factor: 5.209

10.  Characterization of a murine model of cardiorenal syndrome type 1 by high-resolution Doppler sonography.

Authors:  P Pesce; L Cecchetto; S Brocco; M Bolognesi; K Sodhi; N G Abraham; D Sacerdoti
Journal:  J Ultrasound       Date:  2014-09-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.